Cover ImageSALE
市場調查報告書

血流感染檢驗的全球市場:2016∼2020年

Global Blood Stream Infection Testing Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 397910
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
血流感染檢驗的全球市場:2016∼2020年 Global Blood Stream Infection Testing Market 2016-2020
出版日期: 2016年11月09日 內容資訊: 英文 82 Pages
簡介

血液中的細菌和真菌帶來血流感染。這些侵入血液引起肺炎和腦膜炎,敗血症,AIDS等重度的併發症和感染疾病。全球血流感染檢驗市場,預計2016∼2020年以7.75%的年複合成長率擴大。

本報告提供全球血流感染檢驗市場相關調查,市場趨勢與課題,各地區趨勢,及加入此市場的主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第6章 各產品市場區隔

  • 市場概要
  • 設備
  • 消耗品

第7章 各用途市場市場區隔

  • 菌血症
  • 真正菌血症
  • 抗酸菌

第8章 各技術市場區隔

  • 市場概要
  • 傳統的血流感染檢驗
  • 就地檢驗(POCT)
  • 核酸檢驗

第9章 各終端用戶市場區隔

  • 醫院
  • 診斷臨床試驗所

第10章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第11章 推動市場的要素

  • 院內感染的發病率上升擴大患者數
  • 數位技術的患者中心的醫療
  • 對捐血的意識提升擴大BSI檢驗市場需求

第12章 促進要素的影響

第13章 市場課題

  • 成本高阻礙市場成長
  • 有利的償付不足降低對患者的引進率
  • 嚴格法律規章政策阻止新的技術的進入

第14章 促進要素與課題的影響

第15章 市場趨勢

第16章 供應商環境

  • 競爭模式
  • BD
  • bioMerieux
  • Cepheid
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • 其他值得注意的供應商

第17章 附錄

第18章 關於Technavio

目錄
Product Code: IRTNTR10736

About Blood Stream Infection Testing

The presence of bacteria and fungi in blood leads to blood stream infections. Bacteria and fungi enter into the blood and cause severe complications and infections such as pneumonia, meningitis, sepsis and AIDS. Bloodstream infections are caused when bacteria enter the bloodstream; this may occur through a wound, injection, or through a surgical procedure. Symptoms of bacteremia may include fever, chills, malaise, nausea, diarrhea, shortness of breath, and vomiting.

Technavio's analysts forecast the global blood stream infection testing market to grow at a CAGR of 7.75% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global blood stream infection testing market for 2016-2020. To calculate the market size, the report presents the vendor landscape and a corresponding detailed analysis of the top four vendors operating in the market.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Blood Stream Infection Testing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • BD
  • bioMerieux
  • Cepheid
  • Roche Diagnostics
  • Thermo Fisher Scientific

Other Prominent Vendors

  • IRIDICA
  • Alere
  • Beckman Coulter
  • Bruker
  • Nanosphere
  • Siemens
  • Dade Behring
  • AdvanDX
  • Eurogentec
  • AB Sciex

Market driver

  • Growing awareness of blood donation increasing the demand for BSI testing market.
  • For a full, detailed list, view our report

Market challenge

  • Lack of favorable reimbursement reduces adoption rate among patients.
  • For a full, detailed list, view our report

Market trend

  • Increasing demand for infection control committee in hospitals.
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
  • You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by product

  • Market overview
  • Instruments
  • Consumables (blood culture bottles, reagents and assay kits)

PART 07: Market segmentation by application

  • Bacteremia
  • Fungemia
  • Mycobacteria

PART 08: Market segmentation by technology

  • Market overview
  • Conventional blood stream infection test
  • Point of care testing (POCT)
  • Nucleic acid testing

PART 09: Market segmentation by end-user

  • Hospitals
  • Diagnostic clinical laboratories

PART 10: Geographical segmentation

  • Blood stream infection market in Americas
  • Blood stream infection tests market in EMEA
  • Blood stream infection tests market in APAC

PART 11: Market drivers

  • Rising incidence of hospital acquired infection increases patient volume
  • Patient-centered healthcare by digital technology
  • Growing awareness of blood donation increasing the demand for BSI testing market

PART 12: Impact of drivers

PART 13: Market challenges

  • High cost of instruments restricts market growth
  • Lack of favorable reimbursement reduces adoption rate among patients
  • Stringent regulatory policies restrict entry of new technologies

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Focus on early diagnosis
  • Technologically advanced tests save time and cost
  • Increasing demand for infection control committee in hospitals

PART 16: Vendor landscape

  • Competitive scenario
  • BD
  • bioMerieux
  • Cepheid
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Mortality rate of community acquired blood stream infections per year in different regions
  • Exhibit 03: Global blood stream infection testing market 2015-2020 ($ millions)
  • Exhibit 04: Global blood stream infection testing market overview
  • Exhibit 05: Five forces analysis
  • Exhibit 06: Global blood stream infection testing market by products 2015-2020 (%)
  • Exhibit 07: Market strategy analysis of instruments segment
  • Exhibit 08: Global blood stream infection testing instruments market 2015-2020 ($ millions)
  • Exhibit 09: Market strategy analysis of consumable segment
  • Exhibit 10: Global blood stream infection testing consumables market 2015-2020 ($ millions)
  • Exhibit 11: Top ten bacterimia blood stream infections in 2015
  • Exhibit 12: Global blood stream infections testing market by products
  • Exhibit 13: Global blood stream infection testing market share by technology 2015-2020 (%)
  • Exhibit 14: Global conventional blood stream infection testing market 2015-2020 ($ millions)
  • Exhibit 15: The laboratory and POC testing process
  • Exhibit 16: Global blood stream infection testing market by end-user 2015-2020 (%)
  • Exhibit 17: Blood stream infection testing market revenue in the Americas 2015-2020 ($ millions)
  • Exhibit 18: Blood stream infection testing market in Americas
  • Exhibit 19: Blood stream infection testing market revenue in EMEA 2015-2020 ($ millions)
  • Exhibit 20: Blood stream infection testing market in EMEA
  • Exhibit 21: Blood stream infection testing market revenue in APAC 2015-2020 ($ millions)
  • Exhibit 22: Blood stream infection testing market in APAC
  • Exhibit 23: Impact of driver
  • Exhibit 24: Price of different sequencers of different companies
  • Exhibit 25: Government regulatory stages of blood stream infection devices and consumables
  • Exhibit 26: Impact of drivers and challenges
  • Exhibit 27: Reasons for hospital acquired blood stream infection
  • Exhibit 28: Competitive structure of vendors in blood stream infection testing market
  • Exhibit 29: Strength assessment
  • Exhibit 30: BD: Strategy assessment
  • Exhibit 31: BD opportunity assessment
  • Exhibit 32: bioMerieux strength assessment
  • Exhibit 33: bioMerieux strategy assessment
  • Exhibit 34: bioMerieux: Opportunity assessment
  • Exhibit 35: Cepheid: Strength assessment
  • Exhibit 36: Cepheid: Strategy assessment
  • Exhibit 37: Cepheid opportunity assessment
  • Exhibit 38: Roche Diagnostics: Strength assessment
  • Exhibit 39: Roche Diagnostics: Strategy assessment
  • Exhibit 40: Roche Diagnostics: Opportunity assessment
  • Exhibit 41: Thermo Fisher Scientific: Strength assessment
  • Exhibit 42: Thermo Fisher Scientific: Strategy assessment
  • Exhibit 43: Thermo Fisher Scientific: Opportunity assessment
Back to Top